Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oncoinvent ASA ( (BRRGF) ) has shared an update.
Oncoinvent reported a productive second half of 2025, highlighted by positive final Phase 1 data for Radspherin in ovarian cancer and the publication of these results in Gynecologic Oncology, as well as final safety and efficacy data from a Phase 1/2a colorectal cancer trial presented at an international peritoneal malignancies congress. The company also advanced its randomized Phase 2 ovarian cancer trial, expanded trial sites in early 2026, and presented encouraging 24‑month follow‑up data, reinforcing Radspherin’s safety and potential efficacy profile.
Strategically, Oncoinvent completed its merger with BerGenBio, uplisted to the main Oslo Stock Exchange and raised NOK 130 million in equity, moves that strengthen its capital base and market visibility ahead of a planned Phase 2 interim readout. The appointment of a new chief financial officer and growing clinical and scientific exposure position the company to capitalize on what it frames as blockbuster potential and to sharpen its competitive standing in post‑surgical oncology care.
More about Oncoinvent ASA
Oncoinvent ASA is a Norwegian biotechnology company focused on developing Radspherin, a receptor-independent alpha radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery. The therapy targets ovarian and colorectal cancers initially, aiming to prevent or delay recurrence in the peritoneal cavity with a single, localized dose that integrates into existing surgical workflows and avoids significant systemic toxicity.
Average Trading Volume: 16,189
Current Market Cap: NOK207.4M
For detailed information about BRRGF stock, go to TipRanks’ Stock Analysis page.